Recent Advances in Therapeutic Antibody

Dear Colleagues,

The development of therapeutic monoclonal antibodies (mAbs) has remarkably evolved over the past 10 years, and healthcare will still be largely driven by these biologics for the foreseeable decades. Indeed, the number of full-length mAbs, including biosimilars, and derivatives such as Fc-fusion proteins or drug-conjugates, are now part of the therapeutic arsenal. In particular, the arrival of antibodies modulating the immune checkpoints has brought a significant improvement in the field of oncology, while successes in the field of inflammation and autoimmunity have also been confirmed. However, other medical areas covered by the use of mAbs have also expanded, resulting in many new indications. With regard to new formats, multi-specific and novel shapes, such as nanobodies, are mostly in earlier stages of development, but the way forward is promising and exciting.

All these new and rapid advances require frequent updates, and we are pleased to invite you to be part of this Special Issue, in order to share your contributions to the development of therapeutic mAbs.

The aim is to gain insight the following topics: development of novel forms of antibody products, optimization of next-generation products, towards the engineering methods to improve the pharmacokinetics or efficacy/specificity, reduce immunogenicity, etc. New topics about (but not limited to) the improvement of the production processes, including producing-cells engineering, analytical methods improvement, and new formulations, are also welcome.

This Special Issue will be composed of original research articles and reviews. We are looking forward to receiving your contributions. Let us see what is really recent in the therapeutic antibodies area.

Dr. Isabelle Turbica
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.